Business
Perimeter Medical Imaging AI Announces Strong Third Quarter 2025 Financial Results
Perimeter Medical Imaging AI Announces Strong Third Quarter 2025 Financial Results Canada...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n\n\nPerimeter Medical Imaging AI Announces Strong Third Quarter 2025 Financial Results\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\nCanada NewsWire\n\n\nWhile FDA reviews PMA application for the upcoming Perimeter B-Series (Company continues to anticipate Agency's decision in H1-2026) , commercial market traction with the current S-Series has grown\nQ3-2025 revenue growth increased despite summer seasonality, resulting in record nine-month revenue, while operating expenses down 34% YoY, and 30% QoQ\nConference Call/Webcast Scheduled for today at 5 pm ET\nTORONTO and DALLAS, Nov. 12, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (\"Perimeter\" or the \"Company\"), a commercial-stage medical technology company, today reported financial results for its third quarter ended September 30, 2025 and provided a corporate update. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.\n\"The strong business momentum from the second quarter carried through the third quarter, reinforcing the traction we are building across our commercial and development initiatives,\" said Perimeter's CEO, Mr. Adrian Mendes. \"Surgeons across a growing number of top medical centers are now using our S-Series to improve intra-operative decision-making and patient outcomes. And each new installation enhances awareness of our upcoming B-Series, an AI-powered advancement that has the potential to transform the standard of care. With the Breakthrough Device Designation and ongoing collaboration with the FDA, we continue to anticipate a regulatory decision in the first half of 2026. We believe Perimeter is at an important inflection point, as we expand clinical adoption and prepare to bring game-changing AI innovation to operating rooms nationwide.\"\nBusiness Highlights \nCurrent Perimeter S-Series OCT (\"Perimeter S-Series\") Device\nThe Company conti...